Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Clinical trial NCT03957551 · TERMINATED

Trial details

NCT number: NCT03957551
Sponsor: John Rieth
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Metastatic Melanoma

Start date: 2019-08-27
Primary completion: 2024-06-10
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.